Top Key Companies for Molecular Residual Disease Detection Market: Adaptive, Guardant Health, Invitae, Cergentis B.V, LexentBio, Natera, BGI, Zhiben Medical, Burning Rock Medicine, Huidu Medical, Zhenhe Technology, ExactSciences.
Global Molecular Residual Disease Detection Market Size was estimated at USD 103700 million in 2022 and is projected to reach USD 142174.73 million by 2028, exhibiting a CAGR of 5.4% during the forecast period.
Global Molecular Residual Disease Detection Market Overview And Scope:
The Global Molecular Residual Disease Detection Market Report 2026 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Molecular Residual Disease Detection utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2026 and 2035. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Molecular Residual Disease Detection Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Molecular Residual Disease Detection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Molecular Residual Disease Detection market.
Global Molecular Residual Disease Detection Market Segmentation
By Type, Molecular Residual Disease Detection market has been segmented into:
Tumor-informed Assays
Tumor-agnostic Assays
By Application, Molecular Residual Disease Detection market has been segmented into:
Prognosis
Adjuvant Treatment Decision-Making
Surveillance for Postoperative Recurrence
Other
Regional Analysis of Molecular Residual Disease Detection Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Molecular Residual Disease Detection Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Molecular Residual Disease Detection market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Molecular Residual Disease Detection market.
Top Key Companies Covered in Molecular Residual Disease Detection market are:
Adaptive
Guardant Health
Invitae
Cergentis B.V
LexentBio
Natera
BGI
Zhiben Medical
Burning Rock Medicine
Huidu Medical
Zhenhe Technology
ExactSciences
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Molecular Residual Disease Detection Market by Type
5.1 Molecular Residual Disease Detection Market Overview Snapshot and Growth Engine
5.2 Molecular Residual Disease Detection Market Overview
5.3 Tumor-informed Assays
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Tumor-informed Assays: Geographic Segmentation
5.4 Tumor-agnostic Assays
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Tumor-agnostic Assays: Geographic Segmentation
Chapter 6: Molecular Residual Disease Detection Market by Application
6.1 Molecular Residual Disease Detection Market Overview Snapshot and Growth Engine
6.2 Molecular Residual Disease Detection Market Overview
6.3 Prognosis
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2026-2035F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Prognosis: Geographic Segmentation
6.4 Adjuvant Treatment Decision-Making
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2026-2035F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Adjuvant Treatment Decision-Making: Geographic Segmentation
6.5 Surveillance for Postoperative Recurrence
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2026-2035F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Surveillance for Postoperative Recurrence: Geographic Segmentation
6.6 Other
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2026-2035F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Molecular Residual Disease Detection Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Molecular Residual Disease Detection Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Molecular Residual Disease Detection Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 ADAPTIVE
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 GUARDANT HEALTH
7.4 INVITAE
7.5 CERGENTIS B.V
7.6 LEXENTBIO
7.7 NATERA
7.8 BGI
7.9 ZHIBEN MEDICAL
7.10 BURNING ROCK MEDICINE
7.11 HUIDU MEDICAL
7.12 ZHENHE TECHNOLOGY
7.13 EXACTSCIENCES
Chapter 8: Global Molecular Residual Disease Detection Market Analysis, Insights and Forecast, 2026-2035
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Tumor-informed Assays
8.2.2 Tumor-agnostic Assays
8.3 Historic and Forecasted Market Size By Application
8.3.1 Prognosis
8.3.2 Adjuvant Treatment Decision-Making
8.3.3 Surveillance for Postoperative Recurrence
8.3.4 Other
Chapter 9: North America Molecular Residual Disease Detection Market Analysis, Insights and Forecast, 2026-2035
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Tumor-informed Assays
9.4.2 Tumor-agnostic Assays
9.5 Historic and Forecasted Market Size By Application
9.5.1 Prognosis
9.5.2 Adjuvant Treatment Decision-Making
9.5.3 Surveillance for Postoperative Recurrence
9.5.4 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Molecular Residual Disease Detection Market Analysis, Insights and Forecast, 2026-2035
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Tumor-informed Assays
10.4.2 Tumor-agnostic Assays
10.5 Historic and Forecasted Market Size By Application
10.5.1 Prognosis
10.5.2 Adjuvant Treatment Decision-Making
10.5.3 Surveillance for Postoperative Recurrence
10.5.4 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Molecular Residual Disease Detection Market Analysis, Insights and Forecast, 2026-2035
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Tumor-informed Assays
11.4.2 Tumor-agnostic Assays
11.5 Historic and Forecasted Market Size By Application
11.5.1 Prognosis
11.5.2 Adjuvant Treatment Decision-Making
11.5.3 Surveillance for Postoperative Recurrence
11.5.4 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Molecular Residual Disease Detection Market Analysis, Insights and Forecast, 2026-2035
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Tumor-informed Assays
12.4.2 Tumor-agnostic Assays
12.5 Historic and Forecasted Market Size By Application
12.5.1 Prognosis
12.5.2 Adjuvant Treatment Decision-Making
12.5.3 Surveillance for Postoperative Recurrence
12.5.4 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Molecular Residual Disease Detection Market Analysis, Insights and Forecast, 2026-2035
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Tumor-informed Assays
13.4.2 Tumor-agnostic Assays
13.5 Historic and Forecasted Market Size By Application
13.5.1 Prognosis
13.5.2 Adjuvant Treatment Decision-Making
13.5.3 Surveillance for Postoperative Recurrence
13.5.4 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Molecular Residual Disease Detection Market Analysis, Insights and Forecast, 2026-2035
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Tumor-informed Assays
14.4.2 Tumor-agnostic Assays
14.5 Historic and Forecasted Market Size By Application
14.5.1 Prognosis
14.5.2 Adjuvant Treatment Decision-Making
14.5.3 Surveillance for Postoperative Recurrence
14.5.4 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Molecular Residual Disease Detection Scope:
|
Report Data
|
Molecular Residual Disease Detection Market
|
|
Molecular Residual Disease Detection Market Size in 2025
|
USD XX million
|
|
Molecular Residual Disease Detection CAGR 2025 - 2032
|
XX%
|
|
Molecular Residual Disease Detection Base Year
|
2024
|
|
Molecular Residual Disease Detection Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Adaptive, Guardant Health, Invitae, Cergentis B.V, LexentBio, Natera, BGI, Zhiben Medical, Burning Rock Medicine, Huidu Medical, Zhenhe Technology, ExactSciences.
|
|
Key Segments
|
By Type
Tumor-informed Assays
Tumor-agnostic Assays
By Applications
Prognosis
Adjuvant Treatment Decision-Making
Surveillance for Postoperative Recurrence
Other
|
